Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease

Nature Medicine

Volumn 17, Issue 3, 2011, Pages 372-377

  Harari, Alexandre ^a,b   Rozot, Virginie ^a   Enders, Felicitas Bellutti ^a   Perreau, Matthieu ^a   Stalder, Jesica Mazza ^a   Nicod, Laurent P ^a   Cavassini, Matthias ^a   Calandra, Thierry ^a   Blanchet, Catherine Lazor ^a   Jaton, Katia ^a   Faouzi, Mohamed ^a   Day, Cheryl L ^c   Hanekom, Willem A ^c   Bart, Pierre Alexandre ^a   Pantaleo, Giuseppe ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Swiss Vaccine Research Institute   (Switzerland)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; INTERLEUKIN 2; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS;

CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79952449129     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2299     Document Type: Article

References (22)

1. Kaufmann, S.H. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1, 20-30 (2001). (Pubitemid 33741972)
2. Flynn, J.L. & Chan, J. Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93-129 (2001). (Pubitemid 32368031)
3. Lalvani, A. et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357, 2017-2021 (2001). (Pubitemid 32592390)
4. Ewer, K. et al. Comparison of T cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361, 1168-1173 (2003). (Pubitemid 36398385)
5. Meier, T., Eulenbruch, H.P., Wrighton-Smith, P., Enders, G. & Regnath, T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur. J. Clin. Microbiol. Infect. Dis. 24, 529-536 (2005). (Pubitemid 41414002)
6. Jasmer, R.M., Nahid, P. & Hopewell, P.C. Clinical practice. Latent tuberculosis infection. N. Engl. J. Med. 347, 1860-1866 (2002). (Pubitemid 35417778)
7. Betts, M.R. et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107, 4781-4789 (2006). (Pubitemid 43882629)
8. Harari, A. et al. Functional signatures of protective antiviral T cell immunity in human virus infections. Immunol. Rev. 211, 236-254 (2006). (Pubitemid 43882976)
9. Pantaleo, G. & Harari, A. Functional signatures in antiviral T cell immunity for monitoring virus-associated diseases. Nat. Rev. Immunol. 6, 417-423 (2006).
10. Pantaleo, G. & Koup, R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10, 806-810 (2004). (Pubitemid 39070851)
11. Day, C.L. et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J. Infect. Dis. 197, 990-999 (2008). (Pubitemid 351590027)
12. Sutherland, J.S., Adetifa, I.M., Hill, P.C., Adegbola, R.A. & Ota, M.O. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur. J. Immunol. 39, 723-729 (2009).
13. Flynn, J.L. et al. Tumor necrosis factor- is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2, 561-572 (1995).
14. Feldmann, M. & Maini, R.N. Anti-TNF therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163-196 (2001). (Pubitemid 32368033)
15. Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932-1939 (1999).
16. Berry, M.P. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977 (2010).
17. Lamoreaux, L., Roederer, M. & Koup, R. Intracellular cytokine optimization and standard operating procedure. Nat. Protoc. 1, 1507-1516 (2006).
18. Harari, A. et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional and long-lasting T cell responses. J. Exp. Med. 205, 63-77 (2008). (Pubitemid 351185716)
19. Zimmerli, S.C. et al. HIV-1-specific IFN-/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. USA 102, 7239-7244 (2005). (Pubitemid 40696363)
20. Griner, P.F., Mayewski, R.J., Mushlin, A.I. & Greenland, P. Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann. Intern. Med. 94, 557-592 (1981).
21. Metz, C.E. Basic principles of ROC analysis. Semin. Nucl. Med. 8, 283-298 (1978). (Pubitemid 9075026)
22. Zweig, M.H. & Campbell, G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39, 561-577 (1993). (Pubitemid 23118304)